SCHEMBL5544520

SCHEMBL5544520

O=[C]CCc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.48
GPR84 Q9NQS5 1/20 0.46
EPHX2 P34913 3/20 0.43
LTA4H P09960 1/20 0.43
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
SLC6A4 P31645 5/20 0.41
SLC6A3 Q01959 4/20 0.41
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40
FFAR1 O14842 2/20 0.40
ACACB O00763 1/20 0.40
FFAR4 Q5NUL3 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
CHRM5 P08912 1/20 0.39
EPHX1 P07099 1/20 0.39
TRPV1 Q8NER1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537169 0.89 DAO (0.46) DAOGPR84EPHX2LTA4HALDH1A1
SCHEMBL4609982 0.88 DAO (0.44) DAOGPR84EPHX2LTA4HALDH1A1
SCHEMBL5546116 0.86 DAO (0.43) DAOGPR84EPHX2LTA4HALDH1A1
SCHEMBL4714751 0.81 PDE4A (0.46) DAOGPR84EPHX2LTA4HALDH1A1
SCHEMBL3941478 0.81 SLC6A4 (0.45) DAOGPR84EPHX2ALDH1A1TSHR
SCHEMBL5537495 0.80 CHRM2 (0.55) DAOFFAR1
SCHEMBL2093903 0.79 DAO (0.46) DAOGPR84EPHX2LTA4HALDH1A1
SCHEMBL700041 0.79 DAO (0.51) DAOGPR84EPHX2LTA4HALDH1A1
SCHEMBL5545903 0.77 EPHX2 (0.49) DAOGPR84EPHX2LTA4HALDH1A1
SCHEMBL30245785 0.77 DAO (0.44) DAOGPR84EPHX2LTA4HALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 DAO 1115/4885GPR84 318/4885EPHX2 3662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.